Skip to main content
Top
Published in: Endocrine Pathology 2/2014

01-06-2014

In Search of a Prognostic Classification of Endocrine Pituitary Tumors

Author: Jacqueline Trouillas

Published in: Endocrine Pathology | Issue 2/2014

Login to get access

Abstract

Pituitary tumors, the most frequent intracranial tumors, are historically considered benign. However, various pieces of clinical evidence and recent advances in pathological and molecular data suggest the need to consider that these tumors are more than an endocrinological disease despite the low incidence of metastasis. We present here a historical and critical review of the classifications of pituitary tumors, including a new prognostic clinicopathological classification based on tumor size, immunohistological subtype (prolactin (PRL), growth hormone (GH), follicle-stimulating hormone and luteinizing hormone (FSH-LH), adrenocorticotropic hormone (ACTH), and thyroid-stimulating hormone (TSH)), and five grades, which take into account invasion and proliferation of the tumors. We also present a brief review of the main markers of tumor behavior. We believe that a better classification of these tumors and the identification of prognostic markers will help the clinician to choose the appropriate therapeutic management.
Literature
1.
go back to reference Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91: 4769-4775PubMedCrossRef Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91: 4769-4775PubMedCrossRef
2.
go back to reference Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72: 377-382CrossRef Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72: 377-382CrossRef
3.
go back to reference Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER, Jr. (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96: 195-208PubMedCrossRef Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER, Jr. (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96: 195-208PubMedCrossRef
4.
go back to reference Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER, Jr. (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114: 336-344PubMedCrossRef Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER, Jr. (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114: 336-344PubMedCrossRef
5.
go back to reference McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41: 1133-1148PubMedCrossRef McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41: 1133-1148PubMedCrossRef
6.
go back to reference Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76: 769-775CrossRef Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76: 769-775CrossRef
7.
go back to reference Lloyd RV, Kovacs K, Young WF J, Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, E. H: (2004) Pituitary tumours: introduction. In chaper 1: Tumours of the pituitary. DeLellis RA, Lloyd RV, Heitz PU, Eng C (ed) World Health Organization Classification of Tumours - Pathology and genetics of tumours of endocrine organs, IARC Press, Lyon, pp 10-13 Lloyd RV, Kovacs K, Young WF J, Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, E. H: (2004) Pituitary tumours: introduction. In chaper 1: Tumours of the pituitary. DeLellis RA, Lloyd RV, Heitz PU, Eng C (ed) World Health Organization Classification of Tumours - Pathology and genetics of tumours of endocrine organs, IARC Press, Lyon, pp 10-13
8.
go back to reference Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J, Tauveron I (2013) Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest 31: 190-196PubMedCrossRef Batisse M, Raverot G, Maqdasy S, Durando X, Sturm N, Montoriol PF, Kemeny JL, Chazal J, Trouillas J, Tauveron I (2013) Aggressive silent GH pituitary tumor resistant to multiple treatments, including temozolomide. Cancer Invest 31: 190-196PubMedCrossRef
9.
go back to reference Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K (2011) Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature. J Clin Endocrinol Metab 96: 2665-2669 Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K (2011) Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature. J Clin Endocrinol Metab 96: 2665-2669
11.
go back to reference Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126: 123-135PubMedCrossRef Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, Francois P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126: 123-135PubMedCrossRef
12.
go back to reference Asa SL, Kovacs K (1983) Histological classification of pituitary disease. Clin Endocrinol Metab 12: 567-596PubMedCrossRef Asa SL, Kovacs K (1983) Histological classification of pituitary disease. Clin Endocrinol Metab 12: 567-596PubMedCrossRef
13.
go back to reference Trouillas J, Cure M, Lheritier M, Guichard Y, Girod C (1974) [Attempted at a cytofunctional classification of 19 pituitary adenomas using histological, immunocytochemical, biometric and ultrastructural data]. Rev Otoneuroophtalmol 46: 223-236PubMed Trouillas J, Cure M, Lheritier M, Guichard Y, Girod C (1974) [Attempted at a cytofunctional classification of 19 pituitary adenomas using histological, immunocytochemical, biometric and ultrastructural data]. Rev Otoneuroophtalmol 46: 223-236PubMed
14.
go back to reference Trouillas J, Girod C (1996) Pathology of pituitary adenomas. In Landolt AM, Vance ML, Reilly PL (ed) Pituitary Adenomas, Churchill Livingstone, New-York, pp 27-46 Trouillas J, Girod C (1996) Pathology of pituitary adenomas. In Landolt AM, Vance ML, Reilly PL (ed) Pituitary Adenomas, Churchill Livingstone, New-York, pp 27-46
15.
go back to reference Girod C, Mazucca M, Trouillas J, Tramu G, Lheritier M, Beauvillain JC, Claustat B, Dubois MP (1980) Light microscopy, fine structure and immunohistochemistry studies of 278 pituitary adenomas. In Derome PJ, Jedynak CP, Peillon F (ed) Pituitary adenomas, Asclepios, Paris, pp 3-18 Girod C, Mazucca M, Trouillas J, Tramu G, Lheritier M, Beauvillain JC, Claustat B, Dubois MP (1980) Light microscopy, fine structure and immunohistochemistry studies of 278 pituitary adenomas. In Derome PJ, Jedynak CP, Peillon F (ed) Pituitary adenomas, Asclepios, Paris, pp 3-18
17.
go back to reference Trouillas J, Girod C, Sassolas G, Claustrat B (1986) The human gonadotropic adenoma: pathologic diagnosis and hormonal correlations in 26 tumors. Semin Diagn Pathol 3: 42-57PubMed Trouillas J, Girod C, Sassolas G, Claustrat B (1986) The human gonadotropic adenoma: pathologic diagnosis and hormonal correlations in 26 tumors. Semin Diagn Pathol 3: 42-57PubMed
18.
go back to reference Trouillas J, Girod C, Sassolas G, Claustrat B, Lheritier M, Dubois MP, Goutelle A (1981) Human pituitary gonadotropic adenoma; histological, immunocytochemical, and ultrastructural and hormonal studies in eight cases. J Pathol 135: 315-336PubMedCrossRef Trouillas J, Girod C, Sassolas G, Claustrat B, Lheritier M, Dubois MP, Goutelle A (1981) Human pituitary gonadotropic adenoma; histological, immunocytochemical, and ultrastructural and hormonal studies in eight cases. J Pathol 135: 315-336PubMedCrossRef
19.
go back to reference Kovacs K, Horvath E, Ryan N, Ezrin C (1980) Null cell adenoma of the human pituitary. Virchows Arch A Pathol Anat Histol 387: 165-174PubMedCrossRef Kovacs K, Horvath E, Ryan N, Ezrin C (1980) Null cell adenoma of the human pituitary. Virchows Arch A Pathol Anat Histol 387: 165-174PubMedCrossRef
20.
go back to reference Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17: 610-638PubMed Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD (1996) Thyrotropin-secreting pituitary tumors. Endocr Rev 17: 610-638PubMed
21.
go back to reference Bertholon-Gregoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J (1999) Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol 140: 519-527PubMedCrossRef Bertholon-Gregoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J (1999) Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol 140: 519-527PubMedCrossRef
22.
go back to reference Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98: 617-638PubMedCentralPubMed Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98: 617-638PubMedCentralPubMed
23.
go back to reference Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, Weiss MH (1981) Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47: 761-771PubMedCrossRef Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, Weiss MH (1981) Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47: 761-771PubMedCrossRef
24.
go back to reference Kovacs K, Scheithauer BW, Horvath E, Lloyd RV (1996) The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 78: 502-510 Kovacs K, Scheithauer BW, Horvath E, Lloyd RV (1996) The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 78: 502-510
25.
go back to reference Trouillas J, Girod C, Loras B, Sassolas G, Claustrat B, Perrin G (1990) [Normal and tumorous human gonadotropic cells]. Ann Endocrinol (Paris) 51: 54-64 Trouillas J, Girod C, Loras B, Sassolas G, Claustrat B, Perrin G (1990) [Normal and tumorous human gonadotropic cells]. Ann Endocrinol (Paris) 51: 54-64
26.
go back to reference Trouillas J, Lheritier M, Cure M, Girod C, Guinet P, Tommasi M, Goutelle A, Allegre GE (1975) L’oncocytome hypophysaire est-il une entité ? Discussion anatomo-clinique à propos de 3 observations personnelles. Lyon Med. 234: 25-35 Trouillas J, Lheritier M, Cure M, Girod C, Guinet P, Tommasi M, Goutelle A, Allegre GE (1975) L’oncocytome hypophysaire est-il une entité ? Discussion anatomo-clinique à propos de 3 observations personnelles. Lyon Med. 234: 25-35
27.
go back to reference Kovacs K, Horvath E (1973) Pituitary "chromophobe" adenoma composed of oncocytes. A light and electron microscopic study. Arch Pathol 95: 235-239PubMed Kovacs K, Horvath E (1973) Pituitary "chromophobe" adenoma composed of oncocytes. A light and electron microscopic study. Arch Pathol 95: 235-239PubMed
28.
go back to reference Thodou E, Argyrakos T, Kontogeorgos G (2007) Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens) 6: 227-232 Thodou E, Argyrakos T, Kontogeorgos G (2007) Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens) 6: 227-232
29.
go back to reference Riva C, Leutner M, Capella C, Usellini L, la Rosa S, Brianza MR, Buffa R (1993) Different expression of chromogranin A and chromogranin B in various types of pituitary adenomas. Zentralbl Pathol 139: 165-170PubMed Riva C, Leutner M, Capella C, Usellini L, la Rosa S, Brianza MR, Buffa R (1993) Different expression of chromogranin A and chromogranin B in various types of pituitary adenomas. Zentralbl Pathol 139: 165-170PubMed
30.
31.
go back to reference Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J (2010) Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur J Endocrinol 163: 35-43PubMedCrossRef Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J (2010) Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur J Endocrinol 163: 35-43PubMedCrossRef
32.
go back to reference Horvath E, Kovacs K, Smith H, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29: 511-524PubMedCrossRef Horvath E, Kovacs K, Smith H, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary-immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29: 511-524PubMedCrossRef
33.
go back to reference Tourniaire J, Trouillas J, Chalendar D, Bonneton-Emptoz A, Goutelle A, Girod C (1985) Somatotropic adenoma manifested by galactorrhea without acromegaly. J. Clin. Endocrinol. Metab. 61: 451-453PubMedCrossRef Tourniaire J, Trouillas J, Chalendar D, Bonneton-Emptoz A, Goutelle A, Girod C (1985) Somatotropic adenoma manifested by galactorrhea without acromegaly. J. Clin. Endocrinol. Metab. 61: 451-453PubMedCrossRef
34.
go back to reference Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M, S. Y (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19: 82-91 Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M, S. Y (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19: 82-91
35.
go back to reference Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF, Jr., Meyer FB, Kuroki T, Riehle DL, Laws ER, Jr. (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59: 341-353; discussion 341-353PubMedCrossRef Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF, Jr., Meyer FB, Kuroki T, Riehle DL, Laws ER, Jr. (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59: 341-353; discussion 341-353PubMedCrossRef
36.
go back to reference Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Diagnosis and Management of Pituitary Carcinomas. J Clin Endocrinol Metab 90: 3089-3099PubMedCrossRef Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Diagnosis and Management of Pituitary Carcinomas. J Clin Endocrinol Metab 90: 3089-3099PubMedCrossRef
37.
go back to reference Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156: 203-216PubMedCrossRef Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156: 203-216PubMedCrossRef
38.
go back to reference Wolfsberger S, Knosp E (2006) Comments on the WHO 2004 classification of pituitary tumors. Acta Neuropathol 111: 66-67PubMedCrossRef Wolfsberger S, Knosp E (2006) Comments on the WHO 2004 classification of pituitary tumors. Acta Neuropathol 111: 66-67PubMedCrossRef
39.
go back to reference Solcia E, Klöppel G, Sobin L: (2000) Histological classification of adenohypophyseal tumours. Springer Heidelberg New-York pp 6-29 Solcia E, Klöppel G, Sobin L: (2000) Histological classification of adenohypophyseal tumours. Springer Heidelberg New-York pp 6-29
40.
go back to reference Figarella-Branger D, Trouillas J (2006) The new WHO classification of human pituitary tumors: comments. Acta Neuropathol 111: 71-72PubMedCrossRef Figarella-Branger D, Trouillas J (2006) The new WHO classification of human pituitary tumors: comments. Acta Neuropathol 111: 71-72PubMedCrossRef
41.
go back to reference Grossman AB (2006) The 2004 World Health Organization classification of pituitary tumors: is it clinically helpful? Acta Neuropathol (Berl) 111: 76-77CrossRef Grossman AB (2006) The 2004 World Health Organization classification of pituitary tumors: is it clinically helpful? Acta Neuropathol (Berl) 111: 76-77CrossRef
42.
go back to reference Laws ER, Jr., Lopes MB (2006) The new WHO classification of pituitary tumors: highlights and areas of controversy. Acta Neuropathol 111: 80-81PubMedCrossRef Laws ER, Jr., Lopes MB (2006) The new WHO classification of pituitary tumors: highlights and areas of controversy. Acta Neuropathol 111: 80-81PubMedCrossRef
43.
go back to reference Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395-401PubMedCentralPubMedCrossRef Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449: 395-401PubMedCentralPubMedCrossRef
44.
go back to reference Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, D. H (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215: 463-469 Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, D. H (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215: 463-469
45.
go back to reference Francois P, Travers N, Lescanne E, Arbeille B, Jan M, Velut S (2010) The interperiosteo-dural concept applied to the perisellar compartment: a microanatomical and electron microscopic study. J Neurosurg 113: 1045-1052PubMedCrossRef Francois P, Travers N, Lescanne E, Arbeille B, Jan M, Velut S (2010) The interperiosteo-dural concept applied to the perisellar compartment: a microanatomical and electron microscopic study. J Neurosurg 113: 1045-1052PubMedCrossRef
46.
go back to reference Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610-617; discussion 617-618PubMedCrossRef Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610-617; discussion 617-618PubMedCrossRef
47.
go back to reference Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, Mazzatenta D, Farnedi A, Menetti F, Marucci G, Foschini MP (2012) A classification tree approach for pituitary adenomas. Hum Pathol 43: 1627-1637PubMedCrossRef Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, Mazzatenta D, Farnedi A, Menetti F, Marucci G, Foschini MP (2012) A classification tree approach for pituitary adenomas. Hum Pathol 43: 1627-1637PubMedCrossRef
48.
go back to reference Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, Lopes MB, Asa SL (2011) Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 135: 640-646PubMed Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, Lopes MB, Asa SL (2011) Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 135: 640-646PubMed
49.
go back to reference Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15: 71-83PubMedCentralPubMedCrossRef Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15: 71-83PubMedCentralPubMedCrossRef
50.
go back to reference Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni M, Marzoli S, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the rick of tumor recurrence. J Neurosurg 108: 525-532PubMedCrossRef Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni M, Marzoli S, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the rick of tumor recurrence. J Neurosurg 108: 525-532PubMedCrossRef
51.
go back to reference Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95: 1708-1716PubMedCrossRef Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95: 1708-1716PubMedCrossRef
52.
go back to reference Kars M, Roelfsema F, Romijn J, Pereira A (2006) Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 155: 523-534PubMedCrossRef Kars M, Roelfsema F, Romijn J, Pereira A (2006) Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 155: 523-534PubMedCrossRef
53.
go back to reference Landman RE, Horwith M, Peterson RE, Khandji AG, Wardlaw SL (2002) Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature. J Clin Endocrinol Metab 87: 3084-3089PubMedCrossRef Landman RE, Horwith M, Peterson RE, Khandji AG, Wardlaw SL (2002) Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature. J Clin Endocrinol Metab 87: 3084-3089PubMedCrossRef
54.
go back to reference Beauchesne P, Trouillas J, Barral F, Brunon J (1995) Gonadotropic pituitary carcinoma: case report. Neurosurgery 37: 810-815; discussion 815-816PubMedCrossRef Beauchesne P, Trouillas J, Barral F, Brunon J (1995) Gonadotropic pituitary carcinoma: case report. Neurosurgery 37: 810-815; discussion 815-816PubMedCrossRef
55.
go back to reference Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF, Jr., Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79: 804-812PubMedCrossRef Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF, Jr., Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79: 804-812PubMedCrossRef
56.
go back to reference Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF, Jr., Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56: 1066-1074; discussion 1066-1074PubMed Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF, Jr., Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56: 1066-1074; discussion 1066-1074PubMed
57.
go back to reference Lubke D, Saeger W (1995) Carcinomas of the pituitary: definition and review of the literature. Gen Diagn Pathol 141: 81-92PubMed Lubke D, Saeger W (1995) Carcinomas of the pituitary: definition and review of the literature. Gen Diagn Pathol 141: 81-92PubMed
58.
go back to reference Trouillas J, Chevallier P, Claustrat B, Hooghe-Peters E, Dubray C, Rousset B, Girod C (1994) Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology 134: 401-410PubMed Trouillas J, Chevallier P, Claustrat B, Hooghe-Peters E, Dubray C, Rousset B, Girod C (1994) Inhibitory effects of the dopamine agonists quinagolide (CV 205-502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology 134: 401-410PubMed
59.
go back to reference Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14: 887-900PubMedCrossRef Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14: 887-900PubMedCrossRef
60.
go back to reference Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J (2010) Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol 326: 30-39PubMedCrossRef Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J (2010) Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol 326: 30-39PubMedCrossRef
61.
go back to reference Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P, Trouillas J, Lachuer J (2011) Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol 21: 533-543PubMed Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P, Trouillas J, Lachuer J (2011) Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol 21: 533-543PubMed
62.
go back to reference Trouillas J, Raverot G, Jouanneau E, Auger C: (2010) Carcinome hypophysaire. In Tumeurs malignes rares.Droz JP, Ray-Coquard I, Peix JL (ed) Springer, Paris, pp 441-445CrossRef Trouillas J, Raverot G, Jouanneau E, Auger C: (2010) Carcinome hypophysaire. In Tumeurs malignes rares.Droz JP, Ray-Coquard I, Peix JL (ed) Springer, Paris, pp 441-445CrossRef
63.
go back to reference Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83: 179-188PubMedCrossRef Kontogeorgos G (2006) Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83: 179-188PubMedCrossRef
64.
go back to reference Gurlek A, Karavitaki N, Ansorge O, Wass JA (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156: 143-153PubMedCrossRef Gurlek A, Karavitaki N, Ansorge O, Wass JA (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156: 143-153PubMedCrossRef
65.
go back to reference Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49: R69-78PubMedCrossRef Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49: R69-78PubMedCrossRef
66.
go back to reference Raverot G, Jouanneau E, Trouillas J (2014) Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol Mar 13 doi: 10.1530/EJE-13-1031 Raverot G, Jouanneau E, Trouillas J (2014) Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. Eur J Endocrinol Mar 13 doi: 10.​1530/​EJE-13-1031
67.
go back to reference Amar AP, Hinton DR, Krieger MD, Weiss MH (1999) Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 2: 117-122PubMedCrossRef Amar AP, Hinton DR, Krieger MD, Weiss MH (1999) Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 2: 117-122PubMedCrossRef
68.
go back to reference Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V (2007) Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157: 141-147PubMedCrossRef Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V (2007) Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157: 141-147PubMedCrossRef
69.
go back to reference Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25: 927-930PubMedCrossRef Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25: 927-930PubMedCrossRef
70.
go back to reference Saeger W, B L, DK L (2008) Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas. Exp Clin Endocrinol Diabetes 116: 80-85 Saeger W, B L, DK L (2008) Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas. Exp Clin Endocrinol Diabetes 116: 80-85
71.
go back to reference Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER, Jr. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38: 99-106; discussion 106-107PubMedCrossRef Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER, Jr. (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38: 99-106; discussion 106-107PubMedCrossRef
72.
go back to reference Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, Jan M, Perrin G, Fischer G, Tabarin A, Rougon G, Figarella-Branger D (2003) Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg 98: 1084-1093PubMedCrossRef Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, Jan M, Perrin G, Fischer G, Tabarin A, Rougon G, Figarella-Branger D (2003) Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg 98: 1084-1093PubMedCrossRef
73.
go back to reference Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9: 103-113PubMedCrossRef Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9: 103-113PubMedCrossRef
74.
go back to reference Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39: 758-766PubMedCrossRef Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39: 758-766PubMedCrossRef
75.
go back to reference Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A (2003) A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88: 5119-5126PubMedCrossRef Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A (2003) A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 88: 5119-5126PubMedCrossRef
76.
go back to reference Ezzat S (2004) Growth factors and their receptors in the genesis and treatment of thyroid cancer. Cancer Treat Res 122: 121-129PubMedCrossRef Ezzat S (2004) Growth factors and their receptors in the genesis and treatment of thyroid cancer. Cancer Treat Res 122: 121-129PubMedCrossRef
77.
go back to reference Daniel L, Trouillas J, Renaud W, Chevallier P, Gouvernet J, Rougon G, Figarella-Branger D (2000) Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy. Cancer Res 60: 80-85PubMed Daniel L, Trouillas J, Renaud W, Chevallier P, Gouvernet J, Rougon G, Figarella-Branger D (2000) Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy. Cancer Res 60: 80-85PubMed
78.
go back to reference Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K (1996) Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir (Wien) 138: 1442-1448CrossRef Kawamoto H, Kawamoto K, Mizoue T, Uozumi T, Arita K, Kurisu K (1996) Matrix metalloproteinase-9 secretion by human pituitary adenomas detected by cell immunoblot analysis. Acta Neurochir (Wien) 138: 1442-1448CrossRef
79.
go back to reference Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol 22: 757-764PubMedCrossRef Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol 22: 757-764PubMedCrossRef
80.
go back to reference Delhase M, Vergani P, Malur A, Velkeniers B, Teugels E, Trouillas J, Hooghe-Peters EL (1993) Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours. J Mol Endocrinol 11: 129-139PubMedCrossRef Delhase M, Vergani P, Malur A, Velkeniers B, Teugels E, Trouillas J, Hooghe-Peters EL (1993) Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours. J Mol Endocrinol 11: 129-139PubMedCrossRef
81.
go back to reference Vallette-Kasic S, Figarella-Branger D, Grino M, Pulichino AM, Dufour H, Grisoli F, Enjalbert A, Drouin J, Brue T (2003) Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs. J Clin Endocrinol Metab 88: 3050-3056PubMedCrossRef Vallette-Kasic S, Figarella-Branger D, Grino M, Pulichino AM, Dufour H, Grisoli F, Enjalbert A, Drouin J, Brue T (2003) Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs. J Clin Endocrinol Metab 88: 3050-3056PubMedCrossRef
82.
go back to reference Asa SL, Bamberger AM, Cao B, Wong M, Parker KL, Ezzat S (1996) The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 81: 2165-2170PubMed Asa SL, Bamberger AM, Cao B, Wong M, Parker KL, Ezzat S (1996) The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 81: 2165-2170PubMed
83.
go back to reference Chinezu L, Vasiljevic A, Jouanneau E, Francois P, Borda A, Trouillas J, Raverot G (2014) Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 45: 71-77PubMedCrossRef Chinezu L, Vasiljevic A, Jouanneau E, Francois P, Borda A, Trouillas J, Raverot G (2014) Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Hum Pathol 45: 71-77PubMedCrossRef
84.
go back to reference Galland F, Lacroix L, Saulnier P, Dessen P, Meduri G, Bernier M, Gaillard S, Guibourdenche J, Fournier T, Evain-Brion D, Bidart JM, Chanson P (2010) Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 17: 361-371PubMedCrossRef Galland F, Lacroix L, Saulnier P, Dessen P, Meduri G, Bernier M, Gaillard S, Guibourdenche J, Fournier T, Evain-Brion D, Bidart JM, Chanson P (2010) Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 17: 361-371PubMedCrossRef
85.
go back to reference Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82: 818-824PubMed Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN (1997) Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 82: 818-824PubMed
86.
go back to reference Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34: 239-277PubMedCentralPubMedCrossRef Beckers A, Aaltonen LA, Daly AF, Karhu A (2013) Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34: 239-277PubMedCentralPubMedCrossRef
87.
go back to reference Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML (2007) Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 157: 1-8PubMedCrossRef Cazabat L, Libe R, Perlemoine K, Rene-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML (2007) Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 157: 1-8PubMedCrossRef
88.
go back to reference Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A (2002) Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87: 457-465PubMedCrossRef Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C, Calender A (2002) Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87: 457-465PubMedCrossRef
89.
go back to reference Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Verges B, Chabre O, Calender A (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32: 534-543PubMedCrossRef Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Verges B, Chabre O, Calender A (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32: 534-543PubMedCrossRef
90.
go back to reference Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, Francois P (2013) Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary 16: 515-522PubMedCrossRef Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, Francois P (2013) Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary 16: 515-522PubMedCrossRef
Metadata
Title
In Search of a Prognostic Classification of Endocrine Pituitary Tumors
Author
Jacqueline Trouillas
Publication date
01-06-2014
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2014
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-014-9322-y

Other articles of this Issue 2/2014

Endocrine Pathology 2/2014 Go to the issue